Current search for heart disease treatment may not be fruitful

New research suggests C-reactive protein does not cause coronary heart disease - <em>News Release</em>

Imperial College London News Release

Under strict embargo for
21.00 British Summer Time
15.00 Central Time (USA)
22.00 Central European time
Tuesday 30 June 2009

A protein used by doctors to indicate a patient's risk of coronary heart disease may have drug developers barking up the wrong treatment tree, according to the authors of a study published today in the Journal of the American Medical Association (JAMA). Their research suggests that C-reactive protein, an enticing target for scientists working on new treatments for coronary heart disease, may not have a role in causing the disease, even though it is a predictive marker.

Coronary heart disease is the leading cause of death worldwide and is particularly common in Western countries, including the UK, where it is responsible for over 100,000 deaths per year. It is caused by atherosclerosis, where plaques and fatty acids build up in the walls of the arteries.

The progression of the disease from early to later, sometimes fatal, stages involves inflammation. There is strong interest in measuring levels of C-reactive protein in a patient's blood, because it is a marker of inflammation.

Previously, scientists had not known whether C-reactive protein causes coronary heart disease, even though a number of studies over the past 12 years have indicated that it is a risk indicator.

Today's study, by researchers from Imperial College London and 12 other universities and institutes in Europe and North America, looks at the genes that control C-reactive protein levels in blood and their effect on the risk of coronary heart disease. Variations in the gene that codes for C-reactive protein were not associated with risk of coronary heart disease, which the authors say argues against C-reactive protein being directly involved in causing the disease. However, interest still remains in whether C-reactive protein is a useful marker of disease risk.

In the same study, the authors identified genetic variations in three other genes associated with C-reactive protein, which according to the authors, may also be associated with a person's risk of coronary heart disease.

Professor Paul Elliott, lead author of the paper, from the Department of Epidemiology and Public Health at Imperial College London, said: "Coronary heart disease is a common cause of death, especially in the UK and other western countries, and scientists have been looking for new ways to treat the disease and reduce mortality. Some researchers thought C-reactive protein would be a good molecule to target, as raised levels of this protein in the blood are associated with increased risk of coronary heart disease. However our research suggests that the association may not be causal, so attempts to target this protein to reduce the risk of the disease are unlikely to be fruitful."

The level of C-reactive protein in a patient's blood can indicate their risk of heart disease

"We have also discovered new genetic variations that are associated with coronary heart disease. If confirmed in other studies, these might give clues to identify new targets to treat the disease," added Professor Elliott.

The researchers identified 160 genetic variations in 5 genetic regions associated with C-reactive protein levels by carrying out a Genome-Wide Association Study involving 17,967 people.

Two of the genetic regions identified in this study have not previously been associated with risk of coronary heart disease. These genes code for receptors involved in regulating appetite and weight, and inflammation. Further research is needed to confirm whether they also confer susceptibility to coronary heart disease.

The results of further studies showed that there was no significant difference in the frequency of variations in the gene that codes for C-reactive protein between people with and without the disease. This suggests that C-reactive protein does not cause coronary heart disease.

The researchers reached their conclusions by comparing data from different studies showing the association between these genetic variations and coronary heart disease. They looked at a total of 28,112 people with the disease and 100,823 people without the disease.

-Ends-

For further information please contact:

Lucy Goodchild
Press Officer
Imperial College London
e-mail: lucy.goodchild@imperial.ac.uk
Telephone: +44 (0)20 7594 6702 or ext. 46702
Out of hours Duty Press Officer: +44 (0)7803 886 248

Notes to editors:

1. "Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease", JAMA, 30 June 2009
Corresponding author: Professor Paul Elliott, Imperial College London
(For a full list of authors, please see paper)
Full text: follow this link to the JAMA website

2. About Imperial College London

Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 12,000 students and 6,000 staff of the highest international quality.

Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.

Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve health in the UK and globally, tackle climate change and develop clean and sustainable sources of energy.

Website:www.imperial.ac.uk